Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care. We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing functional mushroom nutraceutical products for depression, acute anxiety and sleep disorders. Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa. For more information: www.psyence.com